Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes

AIMS: Immune-mediated beta cell destruction is known to cause hyperglycemia in patients receiving immune checkpoint inhibitor (ICI) cancer therapy. However, it is uncommon, and little is known about the full spectrum of hyperglycemia in patients receiving ICIs. We aimed to characterize the prevalenc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Res Clin Pract
Autores principales: Leiter, Amanda, Carroll, Emily, Brooks, Danielle, Shimol, Jennifer Ben, Eisenberg, Elliot, Wisnivesky, Juan P., Galsky, Matthew D., Gallagher, Emily J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940559/
https://ncbi.nlm.nih.gov/pubmed/33347896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.diabres.2020.108633
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares